Ki67在瘢痕癌中的表达及其临床意义

目的探讨Ki67在瘢痕癌组织中的表达及与患者临床特征的关系。方法应用免疫组化SP法检测Ki67在27例患者瘢痕癌组织中的表达,并结合瘢痕癌患者的临床特征进行分析。结果 27例患者瘢痕癌组织的Ki67检出率为100%。根据Ki67阳性细胞百分率将患者分为3组,≤10%组10例,11%~40%组10例,≥41%组7例。进一步分析发现各组的Ki67阳性细胞百分率与瘢痕溃疡持续时间长短、浸润深度和手术后复发相关,Ki67阳性细胞百分率越高,溃疡持续时间越短(P0.05)、浸润越深(P0.01)、手术后越易复发(P0.05);而与瘢痕病程、溃疡面积无关(P0.05)。结论 Ki67的表达在瘢痕癌浸润深度和术后复发的临床评估中具有重要的指导意义。

Expression of Ki67 in scar carcinoma and its clinical significance

Objective To investigate the expression of Ki67 in scar carcinoma tissues and its correlations with the clinical characteristics of the patients with scar carcinoma. Methods A total of 27 patients who had been pathologically diagnosed as scar carcinoma were enrolled in this retrospective study. The expression of Ki67 in scar carcinoma tissues from those 27 cases was measured by immunohistochemical method. The correlations between Ki67 protein expression and each relevant clinical characteristic were also analyzed. Results The detection rate of Ki67 protein in scar carcinoma tissues was 100% (27/27). According to the percentage of Ki67-positive cells, the patients were divided into three groups, i.e. ≤10% (10 cases), 11%~40% (10 cases) and ≥41% (7 cases). The percentage of Ki67-positive cells in scar carcinoma tissues was significantly associated with ulcer duration(P<0.05), depth of invasion(P<0.01) and post-operation recurrence(P<0.05). However, the expression of Ki67 was not correlated with scar duration and ulcer size in scar carcinoma tissues(P=0.082, P=0.401). Conclusion The expression of Ki67 in scar carcinoma tissues would provide a meaningful evidence for evaluating invasion depth and recurrence after operation.